A phase i study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas

Clinical Cancer Research

Volumn 19, Issue 21, 2013, Pages 6020-6029

  Wagner, Andrew J ^a   Chugh, Rashmi ^c   Rosen, Lee S ^d   Morgan, Jeffrey A ^a   George, Suzanne ^a   Gordon, Michael ^e   Dunbar, Joi ^f   Normant, Emmanuel ^f   Grayzel, David ^f   Demetri, George D ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Pinnacle Oncology Hematology   (United States)

^f Infinity Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; HEAT SHOCK PROTEIN 90; RETASPIMYCIN; TANESPIMYCIN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; ATRIOVENTRICULAR BLOCK; BACKACHE; CONSTIPATION; DIARRHEA; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HUMAN; INJECTION SITE PAIN; LEIOMYOSARCOMA; LIPOSARCOMA; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; METASTASIS; MULTICENTER STUDY; MYALGIA; NAUSEA; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIDE EFFECT; SINUS BRADYCARDIA; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; TIME TO MAXIMUM PLASMA CONCENTRATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZOQUINONES; FEMALE; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; SARCOMA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887058257     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0953     Document Type: Article

References (39)

1. Kasper B, Gil T, D'Hondt V, Gebhart M, Awada A. Novel treatment strategies for soft tissue sarcoma. Crit Rev Oncol Hematol 2007;62: 9-15.
2. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279: 577-80.
3. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003; 21: 4342-9.
4. Janeway KA, Kim SY, Lodish M, Nose V, Rustin P, Gaal J, et al. Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A 2011;108: 314-8.
5. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 2008;26: 620-5.
6. Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008;26: 626-32.
7. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet 2009;373: 1097-104.
8. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347: 472-80.
9. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA 2012;307: 1265-72.
10. Manley PW, Cowan-Jacob SW, Buchdunger E, Fabbro D, Fendrich G, Furet P, et al. Imatinib: a selective tyrosine kinase inhibitor. Eur J Cancer 2002;38 Suppl 5:S19-27.
11. Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 2006;66: 9153-61.
12. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24: 4764-74.
13. Joensuu H. Sunitinib for imatinib-resistant GIST. Lancet 2006;368: 1303-4.
14. Prenen H, Cools J, Mentens N, Folens C, Sciot R, Schoffski P, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12: 2622-7.
15. Roberts KG, Odell AF, Byrnes EM, Baleato RM, Griffith R, Lyons AB, et al. Resistance to c-KIT kinase inhibitors conferred by V654A mutation. Mol Cancer Ther 2007;6: 1159-66.
16. Van Glabbeke M, Verweij J, Casali PG, Le Cesne A, Hohenberger P, Ray-Coquard I, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005;23: 5795-804.
17. Meyer P, Prodromou C, Hu B, Vaughan C, Roe SM, Panaretou B, et al. Structural and functional analysis of the middle segment of hsp90: implications for ATP hydrolysis and client protein and cochaperone interactions. Mol Cell 2003;11: 647-58.
18. Street TO, Lavery LA, Agard DA. Substrate binding drives large-scale conformational changes in the Hsp90 molecular chaperone. Mol Cell 2011;42: 96-105.
19. Taipale M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010;11: 515-28.
20. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 2009;15: 9-14.
21. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007;32: 517-30.
22. Porter JR, Ge J, Lee J, Normant E, West K. Ansamycin inhibitors of Hsp90: nature's prototype for anti-chaperone therapy. Curr Topics Med Chem 2009;9: 1386-418.
23. Sydor JR, Normant E, Pien CS, Porter JR, Ge J, Grenier L, et al. Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci U S A 2006;103: 17408-13.
24. Fritz C, Tillotson B, Ge J, Normant E, Depew K, Basuki J, et al. Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors. European Journal of Biochemistry Supplement 2008. Abstract nr 148.
25. Maroney AC, Marugan JJ, Mezzasalma TM, Barnakov AN, Garrabrant TA, Weaner LE, et al. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives. Biochemistry 2006;45: 5678-85.
26. Ge J, Normant E, Porter JR, Ali JA, Dembski MS, Gao Y, et al. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17- amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. J Med Chem 2006;49: 4606-15.
27. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm M, Fritz L, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425: 407-10.
28. Workman P, Burrows F, Neckers L, Rosen N. Drugging the cancer chaperone HSP90: combinatorial therapeutic exploitation of oncogene addiction and tumor stress. Ann N Y Acad Sci 2007;1113: 202-16.
29. Dewaele B, Wasag B, Cools J, Sciot R, Prenen H, Vandenberghe P, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI- 504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008;14: 5749-58.
30. Floris G, Debiec-Rychter M, Wozniak A, Stefan C, Normant E, Faa G, et al. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage and cell proliferation arrest in xenografts models of gastrointestinal stromal tumors. Mol Cancer Ther 2011; 10: 1897-908.
31. Floris G, Debiec-Rychter M, Sciot R, Stefan C, Wozniak A, Machiels K, et al. Efficacy of IPI-504 "a novel inhibitor of heat shock protein 90" in a preclinical mouse model of gastro intestinal stromal tumor (GIST). In: Proceedings of the 100th Annual Meeting of the American Association of Cancer Research (AACR); 2009 Apr 18-22; Denver, CO. Abstract nr 4692.
32. May WA,Gishizky ML, Lessnick SL, Lunsford LB, Lewis BC, Delattre O, et al. Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation. Proc Natl Acad Sci U S A 1993;90: 5752-6.
33. Terry J, Lubieniecka JM, Kwan W, Liu S, Nielsen TO. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin Cancer Res 2005;11: 5631-8.
34. Wagner AJ, Morgan JA, Chugh R, Rosen LS, George S, Gordon MS, et al. Inhibition of heat shock protein (HSP90) with the novel agent IPI- 504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trial. ASCO Annual Meeting Proceedings, 2008 Abstract nr 10503.
35. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-16.
36. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35: 1773-82.
37. MacRae C, Richardson PG, Walker JW, Grayzel DS, Demetri GD. Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced cancer. Published in conjunction with the 2009 ASCO Annual Meeting. J Clin Oncol27, 2009 (suppl; abstr e14539).
38. Demetri G, Le Cesne A, Von Mehren M, Chmielowski B, Bauer S, Chow W, et al. Final results from a Phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of tyrosine kinase inhibitor (TKI) therapies. In: Proceedings of the ASCO GI Cancers Symposium; 2010 Jan 22-24; Orlando, FL.
39. Cropp G, Solit D, Kersey K, Johnson R, Hannah A. Tanespimycin (17- AAG, KOS-953): No effects on QTc interval using two formulations. In: Proceedings of the 98th Annual Meeting of the American Association for Cancer Research; 2007 Apr 14-18; Los Angeles, CA. Abstract nr 1544.